Literature DB >> 25362972

Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study.

I Belinchón1, F Vanaclocha, P de la Cueva-Dobao, P Coto-Segura, J Labandeira, P Herranz, R Taberner, B Juliá, L Cea-Calvo, L Puig.   

Abstract

BACKGROUND: Increasing evidence indicates a relationship between psoriasis and metabolic syndrome (MS). We evaluated the prevalence of MS in patients receiving systemic treatment for psoriasis in Spain, and its relationship to cardiovascular disease (CVD).
METHODS: This cross-sectional, multicenter, non-interventional study enrolled 368 patients with moderate-to-severe psoriasis requiring systemic treatment. Clinical parameters for psoriasis, CV risk factors, MS and CVD were assessed. Descriptive and logistic regression analyses were performed.
RESULTS: 352 patients were included (median psoriasis duration: 18 years, plaque psoriasis [95.7%], psoriatic arthritis [22.8%]). Overall, 132 patients (37.5%) fulfilled diagnostic criteria for MS; the most prevalent MS components were high blood pressure and increased waist circumference. Patients with MS were older, more likely to be obese and to have a sedentary lifestyle and hypercholesterolemia than those without MS. CVD was more prevalent in patients with MS than in those without (29.5% versus 15.9%, p = 0.002), particularly coronary heart disease (CHD), myocardial infarction and heart failure. MS was independently associated with CVD (OR 1.98, p = 0.018) and CHD (OR 2.02, p = 0.044).
CONCLUSION: The prevalence of MS was high among patients with moderate-to-severe psoriasis requiring systemic treatment, and was associated with a higher prevalence of CVD. Dermatologists should consider implementing simple screening protocols.

Entities:  

Keywords:  Cardiovascular disease; metabolic syndrome; prevalence; psoriasis

Mesh:

Year:  2014        PMID: 25362972     DOI: 10.3109/09546634.2014.983039

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  3 in total

1.  A description of treatment patterns of psoriasis by medical providers and disease severity in US women.

Authors:  Mahroo Tajalli; Tricia Li; Aaron M Drucker; Abrar A Qureshi; Eunyoung Cho
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2020-11-03

2.  Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.

Authors:  Yoshinori Umezawa; Shinya Sakurai; Naoki Hoshii; Hidemi Nakagawa
Journal:  Dermatol Ther (Heidelb)       Date:  2021-02-19

3.  Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis.

Authors:  Esra Adışen; Selda Uzun; Funda Erduran; Mehmet Ali Gürer
Journal:  An Bras Dermatol       Date:  2018-03       Impact factor: 1.896

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.